<DOC>
	<DOCNO>NCT01905202</DOCNO>
	<brief_summary>Secretrol administer 6 month period patient Barrett 's Esophagus safe well tolerate . Further , pH control evaluate distal esophageal mucosa squamocolumnar junction .</brief_summary>
	<brief_title>The Safety Tolerability Secretrol Patients With Barrett 's Esophagus</brief_title>
	<detailed_description>A majority patient Barrett 's esophagus poor distal esophageal pH control . Such patient frequently receive one dose PPI per day attempt improve esophageal pH control . Nocturnal pH control notably difficult achieve many patient suffer Barrett 's esophagus . Recently , adverse effect associate prolonged PPI use ( define 1 year longer ) . These include hypomagnesemia , bone fracture , Clostridium difficile induce diarrhea . High dose PPI well high dose PPI usage ( used hypersecretory condition ) generally find produce different side effect tolerability profile human . This study evaluate effect Secretrol tolerability , adverse effect pH control distal esophagus squamocolumnar junction .</detailed_description>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>Barrett 's esophagus histological confirm Barrett 's ≥ 2 cm length negative indefinite dysplasia/neoplasia . Ages 18 older . Patients sign Informed Consent Form Health Insurance Portability Accountability Act ( HIPAA ) Authorization Form . Clinically relevant data suggest unknown disease require evaluation Primary Investigator . If pacemaker , cardiac defibrillator neurostimulator . Patients renal failure organ transplant . Patients know allergic reaction Proton Pump Inhibitors . Participation another study within 30 day prior screen . Previous enrollment current study . Patient Investigator , family member employee investigational site . Patient know suspect involved alcohol drug abuse . Known suspected history noncompliance medication . Inability follow procedure study ( e.g. , due language problem , psychological disorder ) Patients receive prohibit concomitant medication include PPIs , H2 blocker , sucralfate , misoprostil . Note : patient take dose `` usual '' PPI medication morning visit 2 continue next 24 hour . After PPI permit ( except Secretrol ) Patients receive prohibit concomitant medication include theophylline , clopidogrel , ketoconazole , digoxin , diazepam , warfarin , phenytoin , emtricitabine/nelfinavir/tenofovir , atazanavir , citalopram , emtricitabine/rilpivirine/tenofovir , rilpivirine , nelfinavir , tricyclic antidepressant , baclofen , tacrolimus , cyclosporine , cilostazol , disulfiram , methotrexate , voriconazole . Pregnancy intention become pregnant course study , breast feeding , unwillingness use highly effective mean contraception ( oral contraception intrauterine device ) . Unable complete 48hr esophageal pH monitoring . Prescription NSAID use aspirin use great 325mg daily . History upper gastrointestinal surgery , ZollingerEllison syndrome , esophageal stricture , peptic stricture , duodenal ⁄ gastric ulcer , esophageal motility disorder , IBD , AIDS , pancreatitis , malabsorption , severe cardiovascular pulmonary disease , liver disease , active malignant disease , scleroderma , autonomic peripheral neuropathy , myopathy , underlie disease medication might affect low esophageal sphincter pressure increase acid clearance time . Were unable unwilling fully complete stage study . Unable sign inform consent inability give fully inform consent due language problem , psychological disorder mental deficiency .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Proton Pump Inhibitor</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>pH control</keyword>
	<keyword>Bile Acid</keyword>
</DOC>